Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Feds Closer To Dx Distinguishing Zika From Dengue As HHS Tries To Plug Funding Gap

Executive Summary

The US Department of Health and Human Services gave up on getting new funding from Congress in 2016 to fight Zika virus, and instead juggled its budget this week to throw $81m at the Zika vaccine effort. And while there has been headway on a test to differentiate Zika from Dengue, HHS Secretary Burwell told House Minority Leader Nancy Pelosi in an Aug. 11 letter that NIH currently lacks funds to support diagnostics and other Zika priorities.

You may also be interested in...

US Officials: Work On Tests To Discern Zika From Dengue Could Slow Without Steady Federal Funding

Scientists from US FDA and other health agencies are working to develop and rapidly approve tests that can clearly and quickly detect Zika virus from Dengue fever. But without a steady source of funding for countermeasures, progress to fight Zika may slow, even while the emergence of mosquito-borne diseases accelerates, agency officials said.

NIH's Zika Vaccine Faces Funding Challenge After Skipping Industry Partnership

Agency wanted to move fast, but is now scrambling to pay for Phases I and II trials.

Hologic Wins $4.1m To Advance Zika Blood Screen

The US Biomedical Advanced Research and Development Authority (BARDA) recently granted $4.1m to Hologic to advance development of a blood screen to detect Zika in the blood supply. Also, lawmakers are asking more questions about readiness in the US for detecting emerging infectious diseases and bioterrorism-related toxins.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts